TABLE 5.
Positive peptide pool used in IFN-γ ELISPOT study for subjects with cleared infection or cervical neoplasia
| HLA restriction type | Peptide sequence | Amino acid position | Virus,a protein |
|---|---|---|---|
| A2 | VLGPISGHV | 14-22 | CMV, pp65 |
| A2 | MLNIPSINV | 120-128 | CMV, pp65 |
| A2 | NLVPMVATV | 495-503 | CMV, pp65 |
| A2 | RIFAELEGV | 522-530 | CMV, pp65 |
| A11 | AVFDRKSDAK | 399-408 | EBV, EBNA3B |
| A11 | GPISGHVLK | 16-24 | CMV, pp65 |
| A11 | ATVQGQNLK | 501-509 | CMV, pp65 |
| A24 | RYSIFFDY | 246-253 | EBV, EBNA3A |
| A24 | TYGPVFMCL | 419-427 | EBV, LMP2 |
| A24 | VYALPLKML | 113-121 | CMV, pp65 |
a
EBV, Epstein-Barr virus; CMV, cytomegalovirus.